<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35627142</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Genetic Variability of Inflammation and Oxidative Stress Genes Affects Onset, Progression of the Disease and Survival of Patients with Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">757</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes13050757</ELocationID><Abstract><AbstractText>Inflammation and oxidative stress are recognized as important contributors to amyotrophic lateral sclerosis (ALS) disease pathogenesis. Our aim was to evaluate the impact of selected single-nucleotide polymorphisms in genes involved in inflammation and oxidative stress on ALS susceptibility and modification. One-hundred-and-eighty-five ALS patients and 324 healthy controls were genotyped for nine polymorphisms in seven antioxidant and inflammatory genes using competitive allele-specific PCR. Logistic regression; nonparametric tests and survival analysis were used in the statistical analysis. Investigated polymorphisms were not associated with ALS susceptibility. Carriers of at least one polymorphic <i>SOD2</i> rs4880 T or <i>IL1B</i> rs1071676 C allele more often had bulbar ALS onset (<i>p</i> = 0.036 and <i>p</i> = 0.039; respectively). <i>IL1B</i> rs1071676 was also associated with a higher rate of disease progression (<i>p</i> = 0.015). After adjustment for clinical parameters; carriers of two polymorphic <i>IL1B</i> rs1071676 C alleles had shorter survival (HR = 5.02; 95% CI = 1.92-13.16; <i>p</i> = 0.001); while carriers of at least one polymorphic <i>CAT</i> rs1001179 T allele had longer survival (HR = 0.68; 95% CI = 0.47-0.99; <i>p</i> = 0.046). Our data suggest that common genetic variants in the antioxidant and inflammatory pathways may modify ALS disease. Such genetic information could support the identification of patients that may be responsive to the immune or antioxidant system-based therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ravnik-Glava&#x10d;</LastName><ForeName>Metka</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-3716-4215</Identifier><AffiliationInfo><Affiliation>Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gori&#x10d;ar</LastName><ForeName>Katja</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5673-4458</Identifier><AffiliationInfo><Affiliation>Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogrinc</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5244-459X</Identifier><AffiliationInfo><Affiliation>Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koritnik</LastName><ForeName>Bla&#x17e;</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5083-8261</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Neurophysiology, Division of Neurology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavren&#x10d;i&#x10d;</LastName><ForeName>Jakob Ga&#x161;per</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glava&#x10d;</LastName><ForeName>Damjan</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-9912-3331</Identifier><AffiliationInfo><Affiliation>Department of Molecular Genetics, Institute of Pathology, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Human Genetics &amp; Pharmacogenomics, Faculty of Medicine, University of Maribor, 2000 Maribor, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dol&#x17e;an</LastName><ForeName>Vita</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-6707-6649</Identifier><AffiliationInfo><Affiliation>Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical modifiers</Keyword><Keyword MajorTopicYN="N">genotyping</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">single-nucleotide polymorphisms</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>28</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35627142</ArticleId><ArticleId IdType="pmc">PMC9140599</ArticleId><ArticleId IdType="doi">10.3390/genes13050757</ArticleId><ArticleId IdType="pii">genes13050757</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland L.P., Shneider N.A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2001;344:1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel S.P., Murphy J.R., Alderson M.K., Bryan W., England J.D., Miller R.G., Petajan J.H., Smith S.A., Roelofs R.I., Ziter F., et al. The natural history of amyotrophic lateral sclerosis. Neurology. 1993;43:1316. doi: 10.1212/WNL.43.7.1316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.7.1316</ArticleId><ArticleId IdType="pubmed">8327132</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A., Logroscino G., Traynor B., Collins J., Simeone J., Goldstein L., White L. Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature. Neuroepidemiology. 2013;41:118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., Weishaupt J.H. Update on amyotrophic lateral sclerosis genetics. Curr. Opin. Neurol. 2019;32:735&#x2013;739. doi: 10.1097/WCO.0000000000000737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000737</ArticleId><ArticleId IdType="pubmed">31335339</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor J.P., Brown R.H., Jr., Cleveland D.W. Decoding ALS: From genes to mechanism. Nature. 2016;539:197&#x2013;206. doi: 10.1038/nature20413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>White M.A., Sreedharan J. Amyotrophic lateral sclerosis: Recent genetic highlights. Curr. Opin. Neurol. 2016;29:557&#x2013;564. doi: 10.1097/WCO.0000000000000367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000367</ArticleId><ArticleId IdType="pubmed">27538057</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;land L.-C., Markovinovic A., Jakovac H., De Marchi F., Bilic E., Mazzini L., Kriz J., Munitic I. Immunity in amyotrophic lateral sclerosis: Blurred lines between excessive inflammation and inefficient immune responses. Brain Commun. 2020;2:fcaa124. doi: 10.1093/braincomms/fcaa124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa124</ArticleId><ArticleId IdType="pmc">PMC7585698</ArticleId><ArticleId IdType="pubmed">33134918</ArticleId></ArticleIdList></Reference><Reference><Citation>Obrador E., Salvador-Palmer R., L&#xf3;pez-Blanch R., Jihad-Jebbar A., Vall&#xe9;s S., Estrela J. The Link between Oxidative Stress, Redox Status, Bioenergetics and Mitochondria in the Pathophysiology of ALS. Int. J. Mol. Sci. 2021;22:6352. doi: 10.3390/ijms22126352.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22126352</ArticleId><ArticleId IdType="pmc">PMC8231819</ArticleId><ArticleId IdType="pubmed">34198557</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurcau A. Insights into the Pathogenesis of Neurodegenerative Diseases: Focus on Mitochondrial Dysfunction and Oxidative Stress. Int. J. Mol. Sci. 2021;22:1847. doi: 10.3390/ijms222111847.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222111847</ArticleId><ArticleId IdType="pmc">PMC8584731</ArticleId><ArticleId IdType="pubmed">34769277</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley J., Clarke B., Patani R. The Interplay of RNA Binding Proteins, Oxidative Stress and Mitochondrial Dysfunction in ALS. Antioxidants. 2021;10:552. doi: 10.3390/antiox10040552.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10040552</ArticleId><ArticleId IdType="pmc">PMC8066094</ArticleId><ArticleId IdType="pubmed">33918215</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi S., Abramov A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell. Longev. 2012;2012:428010. doi: 10.1155/2012/428010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/428010</ArticleId><ArticleId IdType="pmc">PMC3362933</ArticleId><ArticleId IdType="pubmed">22685618</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasuri K., Zhang L., Keller J.N. Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis. Free Radic. Biol. Med. 2013;62:170&#x2013;185. doi: 10.1016/j.freeradbiomed.2012.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2012.09.016</ArticleId><ArticleId IdType="pubmed">23000246</ArticleId></ArticleIdList></Reference><Reference><Citation>Power J.H.T., Blumbergs P.C. Cellular glutathione peroxidase in human brain: Cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson&#x2019;s disease and dementia with Lewy bodies. Acta Neuropathol. 2008;117:63&#x2013;73. doi: 10.1007/s00401-008-0438-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0438-3</ArticleId><ArticleId IdType="pubmed">18853169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G.H., Kim J.E., Rhie S.J., Yoon S. The Role of Oxidative Stress in Neurodegenerative Diseases. Exp. Neurobiol. 2015;24:325&#x2013;340. doi: 10.5607/en.2015.24.4.325.</Citation><ArticleIdList><ArticleId IdType="doi">10.5607/en.2015.24.4.325</ArticleId><ArticleId IdType="pmc">PMC4688332</ArticleId><ArticleId IdType="pubmed">26713080</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.-K., Chiang M.-H., Toh E.K.-W., Chang C.-F., Huang T.-H. Molecular mechanism of oxidation-induced TDP-43 RRM1 aggregation and loss of function. FEBS Lett. 2013;587:575&#x2013;582. doi: 10.1016/j.febslet.2013.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2013.01.038</ArticleId><ArticleId IdType="pubmed">23384725</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber S.C., Shaw P.J. Oxidative stress in ALS: Key role in motor neuron injury and therapeutic target. Free Radic. Biol. Med. 2010;48:629&#x2013;641. doi: 10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohgi H., Abe T., Yamazaki K., Murata T., Ishizaki E., Isobe C. Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann. Neurol. 1999;46:129&#x2013;131. doi: 10.1002/1531-8249(199907)46:1&lt;129::AID-ANA21&gt;3.0.CO;2-Y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199907)46:1&lt;129::AID-ANA21&gt;3.0.CO;2-Y</ArticleId><ArticleId IdType="pubmed">10401792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanov M., Brown R.H., Matson W., Smart R., Hayden D., O&#x2019;Donnell H., Beal M.F., Cudkowicz M. Increased oxidative damage to DNA in ALS patients. Free Radic. Biol. Med. 2000;29:652&#x2013;658. doi: 10.1016/S0891-5849(00)00349-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(00)00349-X</ArticleId><ArticleId IdType="pubmed">11033417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H., Santella R.M., Liu X., Bogdanov M., Zipprich J., Wu H.-C., Mahata J., Kilty M., Bednarz K., Bell D., et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph. Lateral Scler. 2008;9:177&#x2013;183. doi: 10.1080/17482960801933942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960801933942</ArticleId><ArticleId IdType="pmc">PMC4332387</ArticleId><ArticleId IdType="pubmed">18574762</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson E.P., Henry Y.K., Henkel J.S., Smith R.G., Appel S.H. Increased lipid peroxidation in sera of ALS patients: A potential biomarker of disease burden. Neurology. 2004;62:1758&#x2013;1765. doi: 10.1212/WNL.62.10.1758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.62.10.1758</ArticleId><ArticleId IdType="pubmed">15159474</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibata N., Nagai R., Uchida K., Horiuchi S., Yamada S., Hirano A., Kawaguchi M., Yamamoto T., Sasaki S., Kobayashi M. Morphological evidence for lipid peroxidation and protein glycoxidation in spinal cords from sporadic amyotrophic lateral sclerosis patients. Brain Res. 2001;917:97&#x2013;104. doi: 10.1016/S0006-8993(01)02926-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(01)02926-2</ArticleId><ArticleId IdType="pubmed">11602233</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzmaurice P., Shaw I.C., Kleiner H.E., Miller R.T., Monks T.J., Lau S.S., Mitchell J.D., Lynch P.G. Evidence for DNA damage in amyotrophic lateral sclerosis. Muscle Nerve. 1996;19:797&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">8609941</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrante R.J., Browne S.E., Shinobu L.A., Bowling A.C., Baik M.J., MacGarvey U., Kowall N.W., Brown R.H., Jr., Beal M.F. Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis. J. Neurochem. 1997;69:2064&#x2013;2074. doi: 10.1046/j.1471-4159.1997.69052064.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69052064.x</ArticleId><ArticleId IdType="pubmed">9349552</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooten K.G., Beers D.R., Zhao W., Appel S.H. Protective and Toxic Neuroinflammation in Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2015;12:364&#x2013;375. doi: 10.1007/s13311-014-0329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-014-0329-3</ArticleId><ArticleId IdType="pmc">PMC4404435</ArticleId><ArticleId IdType="pubmed">25567201</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.F., Shaw P., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature. 2010;465:223&#x2013;226. doi: 10.1038/nature08971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08971</ArticleId><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Lasseigne B.N., Petrovski S., Sapp P.C., Dion P.A., Leblond C.S., Couthouis J., Lu Y.-F., Wang Q., Krueger B.J., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Wieland T., Richter B., Ruf W.P., Schaeffer V., M&#xfc;ller K., Marroquin N., Nordin F., H&#xfc;bers A., Weydt P., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobson-Stone C., Hallupp M., Shahheydari H., Ragagnin A.M.G., Chatterton Z., Carew-Jones F., Shepherd C.E., Stefen H., Paric E., Fath T., et al. CYLD is a causative gene for frontotemporal dementia&#x2014;Amyotrophic lateral sclerosis. Brain. 2020;143:783&#x2013;799. doi: 10.1093/brain/awaa039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa039</ArticleId><ArticleId IdType="pmc">PMC7089666</ArticleId><ArticleId IdType="pubmed">32185393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravel M., B&#xe9;land L.-C., Soucy G., Abdelhamid E., Rahimian R., Gravel C., Kriz J. IL-10 Controls Early Microglial Phenotypes and Disease Onset in ALS Caused by Misfolded Superoxide Dismutase 1. J. Neurosci. 2016;36:1031&#x2013;1048. doi: 10.1523/JNEUROSCI.0854-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0854-15.2016</ArticleId><ArticleId IdType="pmc">PMC6601999</ArticleId><ArticleId IdType="pubmed">26791230</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller A.F., Gravel M., Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp. Neurol. 2011;228:69&#x2013;79. doi: 10.1016/j.expneurol.2010.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.12.010</ArticleId><ArticleId IdType="pubmed">21168408</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke J.G., Bogdanik L., Y&#xe1;&#xf1;ez A., Lall D., Wolf A.J., Muhammad A.K.M.G., Ho R., Carmona S., Vit J.P., Zarrow J., et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324&#x2013;1329. doi: 10.1126/science.aaf1064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A., Moglia C., Balma M., Chio A. Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: A therapeutic opportunity? CNS Neurol. Disord.-Drug Targets. 2010;9:325&#x2013;330. doi: 10.2174/187152710791292657.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152710791292657</ArticleId><ArticleId IdType="pubmed">20406178</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.R., Cagnin A., Turkheimer F.E., Miller C.C.J., Shaw C.E., Brooks D.J., Leigh P.N., Banati R.B. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 2004;15:601&#x2013;609. doi: 10.1016/j.nbd.2003.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2003.12.012</ArticleId><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer P.L., McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26:459&#x2013;470. doi: 10.1002/mus.10191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10191</ArticleId><ArticleId IdType="pubmed">12362410</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkeler A., Boisgard R., Martin A., Tavitian B. Radioisotopic Imaging of Neuroinflammation: FIGURE 1. J. Nucl. Med. 2009;51:1&#x2013;4. doi: 10.2967/jnumed.109.065680.</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.109.065680</ArticleId><ArticleId IdType="pubmed">20008995</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;rcher N.R., Loggia M.L., Lawson R., Chonde D.B., Izquierdo-Garcia D., Yasek J.E., Akeju O., Catana C., Rosen B.R., Cudkowicz M.E., et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: Assessed with [11C]-PBR28. NeuroImage: Clin. 2015;7:409&#x2013;414. doi: 10.1016/j.nicl.2015.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2015.01.009</ArticleId><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves M.C., Fiala M., Dinglasan L.A.V., Liu N.Q., Sayre J., Chiappelli F., van Kooten C., Vinters H.V. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph. Lateral Scler. 2004;5:213&#x2013;219. doi: 10.1080/14660820410020286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410020286</ArticleId><ArticleId IdType="pubmed">15799549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T., Akiyama H., Yamada T., McGeer P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992;140:691&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe P.A., Henderson R.D. The Role of Immune and Inflammatory Mechanisms in ALS. Curr. Mol. Med. 2011;11:246&#x2013;254. doi: 10.2174/156652411795243450.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411795243450</ArticleId><ArticleId IdType="pmc">PMC3182412</ArticleId><ArticleId IdType="pubmed">21375489</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Cao C., Qin X.-Y., Yu Y., Yuan J., Zhao Y., Cheng Y. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: A meta-analysis study. Sci. Rep. 2017;7:9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W., Beers D.R., Hooten K.G., Sieglaff D.H., Zhang A., Kalyana-Sundaram S., Traini C.M., Halsey W.S., Hughes A.M., Sathe G.M., et al. Characterization of Gene Expression Phenotype in Amyotrophic Lateral Sclerosis Monocytes. JAMA Neurol. 2017;74:677&#x2013;685. doi: 10.1001/jamaneurol.2017.0357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2017.0357</ArticleId><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y., Su X., Piao L., Jin Z., Jin R. Involvement of Astrocytes and microRNA Dysregulation in Neurodegenerative Diseases: From Pathogenesis to Therapeutic Potential. Front. Mol. Neurosci. 2021;14:556215. doi: 10.3389/fnmol.2021.556215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.556215</ArticleId><ArticleId IdType="pmc">PMC8010124</ArticleId><ArticleId IdType="pubmed">33815055</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer A., Zurolo E., Prabowo A., Fluiter K., Spliet W.G.M., Van Rijen P.C., Gorter J.A., Aronica E. MicroRNA-146a: A Key Regulator of Astrocyte-Mediated Inflammatory Response. PLoS ONE. 2012;7:e44789. doi: 10.1371/journal.pone.0044789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044789</ArticleId><ArticleId IdType="pmc">PMC3441440</ArticleId><ArticleId IdType="pubmed">23028621</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes C., Cunha C., Nascimento F., Ribeiro J.A., Vaz A.R., Brites D. Cortical Neurotoxic Astrocytes with Early ALS Pathology and miR-146a Deficit Replicate Gliosis Markers of Symptomatic SOD1G93A Mouse Model. Mol. Neurobiol. 2018;56:2137&#x2013;2158. doi: 10.1007/s12035-018-1220-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1220-8</ArticleId><ArticleId IdType="pubmed">29995256</ArticleId></ArticleIdList></Reference><Reference><Citation>Banack S.A., Dunlop R.A., Cox P.A. An miRNA fingerprint using neural-enriched extracellular vesicles from blood plasma: Towards a biomarker for amyotrophic lateral sclerosis/motor neuron disease. Open Biol. 2020;10:200116. doi: 10.1098/rsob.200116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.200116</ArticleId><ArticleId IdType="pmc">PMC7333885</ArticleId><ArticleId IdType="pubmed">32574550</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats K.A., Borchelt D.R., Tansey M.G., Wymer J. Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis. Mol. Neurodegener. 2022;17:11. doi: 10.1186/s13024-022-00515-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-022-00515-1</ArticleId><ArticleId IdType="pmc">PMC8785449</ArticleId><ArticleId IdType="pubmed">35073950</ArticleId></ArticleIdList></Reference><Reference><Citation>Vrabec K., Koritnik B., Leonardis L., Dolenc-Gro&#x161;elj L., Zidar J., Smith B., Vance C., Shaw C., Rogelj B., Glava&#x10d; D., et al. Genetic analysis of amyotrophic lateral sclerosis in the Slovenian population. Neurobiol. Aging. 2014;36:1601.e17&#x2013;1601.e20. doi: 10.1016/j.neurobiolaging.2014.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.11.011</ArticleId><ArticleId IdType="pubmed">25585530</ArticleId></ArticleIdList></Reference><Reference><Citation>Reden&#x161;ek S., Flisar D., Kojovi&#x107; M., Kramberger M.G., Georgiev D., Pirto&#x161;ek Z., Tro&#x161;t M., Dol&#x17e;an V. Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson&#x2019;s disease. J. Neuroinflamm. 2019;16:50. doi: 10.1186/s12974-019-1439-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1439-y</ArticleId><ArticleId IdType="pmc">PMC6393982</ArticleId><ArticleId IdType="pubmed">30813952</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon M.S., Wosiski-Kuhn M., Gillespie R., Caress J., Milligan C. Inflammation, Immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve. 2018;59:10&#x2013;22. doi: 10.1002/mus.26289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26289</ArticleId><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomkins J., Banner S.J., McDermott C., Shaw P. Mutation screening of manganese superoxide dismutase in amyotrophic lateral sclerosis. NeuroReport. 2001;12:2319&#x2013;2322. doi: 10.1097/00001756-200108080-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-200108080-00008</ArticleId><ArticleId IdType="pubmed">11496103</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdmanis P.N., Kabashi E., Dyck A., Hince P., Lee J., Dion P., D&#x2019;Amour M., Souchon F., Bouchard J.P., Salachas F., et al. Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. Neurology. 2008;71:514&#x2013;520. doi: 10.1212/01.wnl.0000324997.21272.0c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000324997.21272.0c</ArticleId><ArticleId IdType="pubmed">18695162</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros J.B.D.S., Santos K.D.F., Azevedo R.M., de Oliveira R.P.D., Leobas A.C.D., Bento D.d.C.P., Santos R.D.S., Reis A.A.D.S. No association of GSTP1 rs1695 polymorphism with amyotrophic lateral sclerosis: A case-control study in the Brazilian population. PLoS ONE. 2021;16:e0247024. doi: 10.1371/journal.pone.0247024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0247024</ArticleId><ArticleId IdType="pmc">PMC7894827</ArticleId><ArticleId IdType="pubmed">33606765</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-L&#xf3;pez A., Gamez J., Syriani E., Morales M., Salvado M., Rodriguez M.J., Mahy N., Vidal-Taboada J.M. CX3CR1 Is a Modifying Gene of Survival and Progression in Amyotrophic Lateral Sclerosis. PLoS ONE. 2014;9:e96528. doi: 10.1371/journal.pone.0096528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0096528</ArticleId><ArticleId IdType="pmc">PMC4013026</ArticleId><ArticleId IdType="pubmed">24806473</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A., Moglia C., Canosa A., Cammarosano S., Ilardi A., Bertuzzo D., Traynor B.J., Brunetti M., Barberis M., Mora G., et al. Common polymorphisms of chemokine (C-X3-C motif) receptor 1 gene modify amyotrophic lateral sclerosis outcome: A population-based study. Muscle Nerve. 2017;57:212&#x2013;216. doi: 10.1002/mus.25653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25653</ArticleId><ArticleId IdType="pmc">PMC5912184</ArticleId><ArticleId IdType="pubmed">28342179</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli R.C., Bolasco G., Pagani F., Maggi L., Scianni M., Panzanelli P., Giustetto M., Ferreira T.A., Guiducci E., Dumas L., et al. Synaptic Pruning by Microglia Is Necessary for Normal Brain Development. Science. 2011;333:1456&#x2013;1458. doi: 10.1126/science.1202529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1202529</ArticleId><ArticleId IdType="pubmed">21778362</ArticleId></ArticleIdList></Reference><Reference><Citation>Walczak M., Lykowska-Szuber L., Plucinska M., Stawczyk-Eder K., Zakerska-Banaszak O., Eder P., Krela-Kazmierczak I., Michalak M., Zywicki M., Karlowski W.M., et al. Is Polymorphism in the Apoptosis and Inflammatory Pathway Genes Associated With a Primary Response to Anti-TNF Therapy in Crohn&#x2019;s Disease Patients? Front. Pharmacol. 2020;11:1207. doi: 10.3389/fphar.2020.01207.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01207</ArticleId><ArticleId IdType="pmc">PMC7456829</ArticleId><ArticleId IdType="pubmed">32922288</ArticleId></ArticleIdList></Reference><Reference><Citation>Esih K., Gori&#x10d;ar K., Rener-Primec Z., Dol&#x17e;an V., Soltirovska-&#x160;alamon A. CARD8 and IL1B Polymorphisms Influence MRI Brain Patterns in Newborns with Hypoxic-Ischemic Encephalopathy Treated with Hypothermia. Antioxidants. 2021;10:96. doi: 10.3390/antiox10010096.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10010096</ArticleId><ArticleId IdType="pmc">PMC7826682</ArticleId><ArticleId IdType="pubmed">33445495</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.A., Gay C.L., Lerdal A., Pullinger C.R., Aouizerat B.E. Cytokine polymorphisms are associated with fatigue in adults living with HIV/AIDS. Brain Behav. Immun. 2014;40:95&#x2013;103. doi: 10.1016/j.bbi.2014.02.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2014.02.017</ArticleId><ArticleId IdType="pmc">PMC4102618</ArticleId><ArticleId IdType="pubmed">24632226</ArticleId></ArticleIdList></Reference><Reference><Citation>Johann S., Heitzer M., Kanagaratnam M., Goswami A., Rizo T., Weis J., Troost D., Beyer C. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia. 2015;63:2260&#x2013;2273. doi: 10.1002/glia.22891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22891</ArticleId><ArticleId IdType="pubmed">26200799</ArticleId></ArticleIdList></Reference><Reference><Citation>Meissner F., Molawi K., Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1&#x3b2; accelerates ALS pathogenesis. Proc. Natl. Acad. Sci. USA. 2010;107:13046&#x2013;13050. doi: 10.1073/pnas.1002396107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1002396107</ArticleId><ArticleId IdType="pmc">PMC2919927</ArticleId><ArticleId IdType="pubmed">20616033</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Ona V.O., Gu&#xe9;gan C., Chen M., Jackson-Lewis V., Andrews L.J., Olszewski A.J., Stieg P.E., Lee J.-P., Przedborski S., et al. Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse Model. Science. 2000;288:335&#x2013;339. doi: 10.1126/science.288.5464.335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.288.5464.335</ArticleId><ArticleId IdType="pubmed">10764647</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellezza I., Grottelli S., Costanzi E., Scarpelli P., Pigna E., Morozzi G., Mezzasoma L., Peirce M.J., Moresi V., Adamo S., et al. Peroxynitrite Activates the NLRP3 Inflammasome Cascade in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2017;55:2350&#x2013;2361. doi: 10.1007/s12035-017-0502-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0502-x</ArticleId><ArticleId IdType="pubmed">28357805</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen M.N., Wuolikainen A., Nilsson A.C., Wirenfeldt M., Forsberg K., Madsen J.S., Lillevang S.T., Brandslund I., Andersen P.M., Asgari N. Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e697. doi: 10.1212/NXI.0000000000000697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000697</ArticleId><ArticleId IdType="pmc">PMC7136052</ArticleId><ArticleId IdType="pubmed">32123048</ArticleId></ArticleIdList></Reference><Reference><Citation>Polverino A., Rucco R., Stillitano I., Bonavita S., Grimaldi M., Minino R., Pesoli M., Trojsi F., D&#x2019;Ursi A.M., Sorrentino G., et al. In Amyotrophic Lateral Sclerosis Blood Cytokines Are Altered, but Do Not Correlate with Changes in Brain Topology. Brain Connect. 2020;10:411&#x2013;421. doi: 10.1089/brain.2020.0741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/brain.2020.0741</ArticleId><ArticleId IdType="pubmed">32731760</ArticleId></ArticleIdList></Reference><Reference><Citation>Italiani P., Carlesi C., Giungato P., Puxeddu I., Borroni B., Boss&#xf9; P., Migliorini P., Siciliano G., Boraschi D. Evaluating the levels of interleukin-1 family cytokines in sporadic amyotrophic lateral sclerosis. J. Neuroinflamm. 2014;11:94. doi: 10.1186/1742-2094-11-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-11-94</ArticleId><ArticleId IdType="pmc">PMC4039322</ArticleId><ArticleId IdType="pubmed">24884937</ArticleId></ArticleIdList></Reference><Reference><Citation>Bresciani G., Cruz I.B.M., De Paz J.A., Cuevas M.J., Gonz&#xe1;lez-Gallego J. The MnSOD Ala16Val SNP: Relevance to human diseases and interaction with environmental factors. Free Radic. Res. 2013;47:781&#x2013;792. doi: 10.3109/10715762.2013.836275.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10715762.2013.836275</ArticleId><ArticleId IdType="pubmed">23952573</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutton A., Imbert A., Igoudjil A., Descatoire V., Cazanave S., Pessayre D., Degoul F. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharm. Genom. 2005;15:311&#x2013;319. doi: 10.1097/01213011-200505000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01213011-200505000-00006</ArticleId><ArticleId IdType="pubmed">15864132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekoue D.N., He C., Diamond A.M., Bonini M.G. Manganese superoxide dismutase and glutathione peroxidase-1 contribute to the rise and fall of mitochondrial reactive oxygen species which drive oncogenesis. Biochim. Biophys. Acta. 2017;1858:628&#x2013;632. doi: 10.1016/j.bbabio.2017.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbabio.2017.01.006</ArticleId><ArticleId IdType="pmc">PMC5689482</ArticleId><ArticleId IdType="pubmed">28087256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bresciani G., Gonz&#xe1;lez-Gallego J., da Cruz I.B., de Paz J.A., Cuevas M.J. The Ala16Val MnSOD gene polymorphism modulates oxidative response to exercise. Clin. Biochem. 2012;46:335&#x2013;340. doi: 10.1016/j.clinbiochem.2012.11.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2012.11.020</ArticleId><ArticleId IdType="pubmed">23219743</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F., Tiloca C., Morelli C., Doretti A., Poletti B., Maderna L., Messina S., Gentilini D., Fogh I., Ratti A., et al. PON1 is a disease modifier gene in amyotrophic lateral sclerosis: Association of the Q192R polymorphism with bulbar onset and reduced survival. Neurol. Sci. 2019;40:1469&#x2013;1473. doi: 10.1007/s10072-019-03834-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03834-2</ArticleId><ArticleId IdType="pubmed">30903418</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg L., Lyren&#xe4;s L., Morgenstern R., de Faire U. A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic. Biol. Med. 2001;30:500&#x2013;505. doi: 10.1016/S0891-5849(00)00487-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(00)00487-1</ArticleId><ArticleId IdType="pubmed">11182520</ArticleId></ArticleIdList></Reference><Reference><Citation>Esih K., Gori&#x10d;ar K., Dol&#x17e;an V., Rener-Primec Z. The association between antioxidant enzyme polymorphisms and cerebral palsy after perinatal hypoxic-ischaemic encephalopathy. Eur. J. Paediatr. Neurol. 2016;20:704&#x2013;708. doi: 10.1016/j.ejpn.2016.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejpn.2016.05.018</ArticleId><ArticleId IdType="pubmed">27302388</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulas A., Fidani L., Kotsis A., Mirtsou V., Petersen R.C., Tangalos E., Hardy J. An association study of a functional catalase gene polymorphism, &#x2212;262C&#x2192;T, and patients with Alzheimer&#x2019;s disease. Neurosci. Lett. 2002;330:210&#x2013;212. doi: 10.1016/S0304-3940(02)00780-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(02)00780-2</ArticleId><ArticleId IdType="pubmed">12231449</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K., Liu X., Wang M., Wang X., Kang H., Lin S., Yang P., Dai C., Xu P., Li S., et al. Two common functional catalase gene polymorphisms (rs1001179 and rs794316) and cancer susceptibility: Evidence from 14,942 cancer cases and 43,285 controls. Oncotarget. 2016;7:62954&#x2013;62965. doi: 10.18632/oncotarget.10617.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.10617</ArticleId><ArticleId IdType="pmc">PMC5325339</ArticleId><ArticleId IdType="pubmed">27449288</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C.-D., Sun Y., Chen N., Huang L., Huang J.-W., Zhu M., Wang T., Ji Y.-L. The Role of Catalase C262T Gene Polymorphism in the Susceptibility and Survival of Cancers. Sci. Rep. 2016;6:26973. doi: 10.1038/srep26973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep26973</ArticleId><ArticleId IdType="pmc">PMC4880922</ArticleId><ArticleId IdType="pubmed">27225983</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikoli&#x107;-Koki&#x107; A., Stevi&#x107; Z., Blagojevi&#x107; D., Davidovi&#x107;-Plav&#x161;i&#x107; B., Jones D.R., Spasi&#x107; M. Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic lateral sclerosis (SALS) and familial ALS patients. Clin. Chem. Lab. Med. (CCLM) 2006;44:589&#x2013;593. doi: 10.1515/CCLM.2006.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/CCLM.2006.111</ArticleId><ArticleId IdType="pubmed">16681429</ArticleId></ArticleIdList></Reference><Reference><Citation>Golenia A., Le&#x15b;kiewicz M., Regulska M., Budziszewska B., Szcz&#x119;sny E., Jagie&#x142;&#x142;a J., Wnuk M., Ostrowska M., Laso&#x144; W., Basta-Kaim A., et al. Catalase activity in blood fractions of patients with sporadic ALS. Pharmacol. Rep. 2014;66:704&#x2013;707. doi: 10.1016/j.pharep.2014.02.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharep.2014.02.021</ArticleId><ArticleId IdType="pubmed">24948075</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu G.N., Kumar A., Chandra R., Puri S., Singh R., Kalita J., Misra U. Oxidant&#x2013;antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease. Neurochem. Int. 2008;52:1284&#x2013;1289. doi: 10.1016/j.neuint.2008.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2008.01.009</ArticleId><ArticleId IdType="pubmed">18308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.-Y., Zhou Z.-R., Che C.-H., Liu C.-Y., He R.-L., Huang H.-P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A. Clinical Manifestation and Management of Amyotrophic Lateral Sclerosis. In: Araki T., editor. Amyotrophic Lateral Sclerosis. Exon Publications; Brisbane, Australia: 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.36255/exonpublications.amyotrophiclateralsclerosis.management.2021</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>